Physician profile
Robert M Marcus
NPI 1588631923
$2,578.30
in general payments reported to CMS, 2019-2025
27 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.74 · 2022: $429 · 2023: $795 · 2024: $648 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $428.04 | 2022-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $390.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $287.33 | 2021-2025 | |
| Pfizer INC. | $248.19 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $205.71 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $151.17 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $146.22 | 2022-2024 | |
| Exact Sciences Corporation | $110.31 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $94.60 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $66.72 | 2021-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $58.72 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $55.92 | 2023-2025 | Repatha, Evenity |
| Dexcom, INC. | $38.28 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.34 | 2023 | Ofev |
| Esperion Therapeutics, INC. | $30.52 | 2021-2025 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.50 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $25.37 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.59 | 2022 | |
| Eisai INC. | $23.91 | 2025 | |
| Boston Scientific Corporation | $22.94 | 2025 | General - Pain Management |
| Bausch Health US, LLC | $22.41 | 2025 | Aplenzin, Wellbutrin |
| Bayer Healthcare Pharmaceuticals INC. | $19.73 | 2022 | |
| Astellas Pharma US INC | $19.07 | 2023 | Veozah |
| Actelion Pharmaceuticals US, INC. | $17.79 | 2025 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.06 | 2025 | Xifaxan |
| Corium, LLC | $14.48 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.